Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience

Vergote, 1992, Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer, Cancer, 69, 741, 10.1002/1097-0142(19920201)69:3<741::AID-CNCR2820690322>3.0.CO;2-G

Ahmed, 1996, Natural history and prognosis of untreated stage I epithelial ovarian carcinoma, J Clin Oncol, 14, 2968, 10.1200/JCO.1996.14.11.2968

Brugghe, 1998, Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment, Gynecol Oncol, 68, 47, 10.1006/gyno.1997.4884

Trimbos, 2003, Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial, J Natl Cancer Inst, 95, 113, 10.1093/jnci/95.2.113

Colombo, 2003, International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer, J Natl Cancer Inst, 95, 125, 10.1093/jnci/95.2.125

Trimbos, 2003, International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma, J Natl Cancer Inst, 95, 105, 10.1093/jnci/95.2.105

McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, 334, 1, 10.1056/NEJM199601043340101

Piccart, 2000, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J Natl Cancer Inst, 92, 699, 10.1093/jnci/92.9.699

Ozols, 2003, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J Clin Oncol, 21, 3194, 10.1200/JCO.2003.02.153

Bell, 2006, Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynaecologic oncology group study, Gynecol Oncol, 102, 432, 10.1016/j.ygyno.2006.06.013

Vergote, 2001, Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma, Lancet, 357, 176, 10.1016/S0140-6736(00)03590-X

Young, 1990, Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials, N Engl J Med, 322, 1021, 10.1056/NEJM199004123221501

Chan, 2008, Prognostic factors for high-risk early-stage epithelial ovarian cancer, Cancer, 112, 2202, 10.1002/cncr.23390

Bamias, 2006, Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group, BMC Cancer, 6, 228, 10.1186/1471-2407-6-228

Kurman, 2010, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, Am J Surg Pathol, 34, 433, 10.1097/PAS.0b013e3181cf3d79

Zanetta, 1998, The accuracy of staging: an important prognostic determination in stage I ovarian carcinoma, Ann Oncol, 9, 1097, 10.1023/A:1008424527668

Bolis, 1995, Adjuvant treatment for early epithelial ovarian cancer: Results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P), Ann Oncol, 6, 887, 10.1093/oxfordjournals.annonc.a059355

Bamias, 2010, Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum–paclitaxel chemotherapy, Cancer, 116, 1462, 10.1002/cncr.24915

Winter, 2007, J Clin Oncol, 25, 3621, 10.1200/JCO.2006.10.2517

Seidman, 2010, Prognostic factors for stage I ovarian carcinoma, Int J Gynecol Pathol, 29, 1, 10.1097/PGP.0b013e3181af2372

Kobel, 2010, Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications, Gynecol Oncol, 116, 50, 10.1016/j.ygyno.2009.09.029

Lee, 1999, Clinically apparent early stage invasive ovarian epithelial carcinoma: should all be treated similarly?, Gynecol Oncol, 74, 252, 10.1006/gyno.1999.5440

Gilks, 2008, Tumor cell type can reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma, Hum Pathol, 39, 1239, 10.1016/j.humpath.2008.01.003

Soslow, 2008, Histologic subtypes of ovarian carcinoma: an overview, Int J Gynecol Pathol, 27, 161

Silveberg, 2000, Histopathological grading of ovarian carcinoma: a review and proposal, Int J Gynecol Pathol, 19, 7, 10.1097/00004347-200001000-00003

Kommoss, 2009, Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study, Vircjows Arch, 454, 249, 10.1007/s00428-009-0725-y

Markman, 2009, An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer, Cancer J, 15, 105, 10.1097/PPO.0b013e31819e31f2

Burger, 2010, Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study, J Clin Oncol, 28, 5s

Perren, 2010

Abaid, 2010, Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma, Oncology, 78, 389, 10.1159/000320579

Chan, 2010, The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study, Gynecol Oncol, 116, 301, 10.1016/j.ygyno.2009.10.073